Boehringer Ingelheim studies BI-905681 in phase I for advanced, unresectable or metastatic tumors Feb. 7, 2020
Phase I results for troriluzole plus nivolumab in patients advanced or refractory solid tumors Feb. 7, 2020
Pan-Cancer Project looks closer, sees more Feb. 5, 2020 By Nuala Moran LONDON – The genomes of 38 different tumor types and the 47 million mutations that fostered their growth are revealed in unprecedented detail in 23 studies published in Nature and other journals on Feb. 6, 2020.Read More
RSS
